Drug Interaction Platform Reducing Adverse Alerts via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug prescription methods often lead to adverse side effects, toxicity, and increased healthcare burdens due to complex drug-drug and gene-drug interactions, particularly in patients taking multiple medications, as existing systems lack efficient tools for real-time monitoring and optimization of drug regimens.
Innovation Solution
A web-based platform, DDI+, integrates with electronic medical records and databases like GENELEX™ and FIRST DATABANK™ to analyze drug interactions, predict adverse effects, and suggest alternative medications, using a Shared Adverse Side Effect Predictor, HealthCare Burden Estimator, and Alternative Drug Suggestion Mechanism to minimize adverse interactions and optimize drug regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive drug interaction analysis is performed using multiple databases and tools, then prediction accuracy of adverse effects is improved, but system complexity and computational time increase
Solution Approach 1:
The system segments the drug interaction analysis into multiple specialized databases (GENELEX for genetic interactions, FIRST DATABANK for drug monographs, Micromedex for clinical outcomes) and processing tools. Each database handles a specific aspect of drug interaction analysis, allowing comprehensive coverage while maintaining manageable complexity through modular organization.
Solution Approach 2:
The patent introduces an intermediary processing layer that integrates data from multiple databases and applies sophisticated algorithms to synthesize comprehensive drug interaction profiles. This intermediary layer manages the complexity by coordinating information flow between databases and presenting integrated results to users.
2Reliability
If real-time monitoring of drug regimens is implemented, then patient safety is improved, but computational resources and processing time are increased
Solution Approach 1:
The system performs preliminary analysis of drug interactions when prescriptions are initially entered or updated in the electronic medical record system. By conducting the computational analysis in advance rather than continuously in real-time, the system ensures patient safety through comprehensive checking while reducing ongoing computational resource requirements.
Solution Approach 2:
The system implements feedback mechanisms that monitor drug regimen changes and trigger analysis only when modifications occur. This event-driven approach maintains patient safety by analyzing relevant changes while minimizing unnecessary computational resource consumption during stable periods.
3Loss of information
If multiple databases and processing tools are integrated, then completeness of drug interaction information is improved, but data integration complexity increases
Solution Approach 1:
The patent merges multiple specialized databases (GENELEX, FIRST DATABANK, Micromedex) and processing tools into a unified integrated system. This consolidation ensures complete drug interaction information by combining the strengths of each source while managing integration complexity through standardized data interfaces and centralized coordination.
4Reliability
If personalized drug regimen optimization is provided, then patient-specific safety is improved, but processing time and computational load increase
Solution Approach 1:
The system applies personalized analysis focused on the specific patient's genetic profile, current medication list, and clinical characteristics. By concentrating computational resources on patient-specific factors rather than performing generic analysis on all possible drug interactions, the system improves patient-specific safety while reducing overall processing time.
Data Source
AI summary
A platform accessible by a user from a web browser/HMO's electronic medical record (EMR) for providing the user with information regarding a patient's drug regimen as well as generating alerts concerning potential adverse effects to a patient from taking a cluster including a plurality of pharmaceutical preparations and various food supplementals/herbals may be in data communication with and configured to obtain information from at least two databases and at least one tool for processing the cluster of pharmaceutical preparations in accordance with the information to generate the alerts to the user.